Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol’s combo demonstrates similar response rate as PD-1 alone, but with much better survival rates in a small melanoma study presented at ASCO. Due to toxicities, including one death, some say combination would need to shore up survival benefit to become first choice in frontline therapy.
You may also be interested in...
Bristol's CheckMate 067 Revives Debate On Rationing Yervoy/Opdivo Combo
Yervoy/Opdivo combo proves significant survival benefit over Yervoy alone in Phase III frontline melanoma study, but is on par with Opdivo alone in patients with higher PD-L1 expression.
Melanoma Approvals Break New Ground In Immunotherapy
First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.
Bristol Offers Yervoy For Free In New Early Melanoma Indication
New program gives free treatment with the checkpoint inhibitor for up to three years to patients taking 10 mg/kg dose as adjuvant therapy after surgery.